Letters to the Editor

First-in-human pharmacokinetic, safety, and preliminary efficacy of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A

State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
Department of Hematology, Zhengzhou People’s Hospital, Zhengzhou
Department of Hematology, Zhengzhou People’s Hospital, Zhengzhou
Department of Hematology, People’s Hospital of Rizhao, Rizhao
Department of Hematology, Jinan Central Hospital, Jinan
Department of Hematology, Jinan Central Hospital, Jinan
Department of Hematology, Affiliated Hospital of Jiangnan University, Yangzhou
Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao
Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao
Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou
Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou
State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
Haematologica Early view Jun 12, 2025 https://doi.org/10.3324/haematol.2024.286964